The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigating the prognostic value of TP53 and PIK3CA mutations in metastatic colorectal cancer (mCRC): Applying Structured Query Language (SQL) algorithms to real-world data from a high-volume U.K. tertiary cancer center.
 
Caroline Fong
No Relationships to Disclose
 
Ali Abdulnabi Suwaidan
No Relationships to Disclose
 
Geraldo Alves de Paula Neto
No Relationships to Disclose
 
Marion Teare
No Relationships to Disclose
 
Elli Bourmpaki
No Relationships to Disclose
 
Clare Peckitt
No Relationships to Disclose
 
David J. Watkins
No Relationships to Disclose
 
Sheela Rao
Consulting or Advisory Role - Bayer; Hookipa Pharma
Speakers' Bureau - Merck Serono
Expert Testimony - Boehringer Ingelheim
 
Naureen Starling
Honoraria - Amgen; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER
Consulting or Advisory Role - AstraZeneca; MSD; Pfizer; SERVIER
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Lilly; Merck; MSD Oncology; Roche
 
Ian Chau
Honoraria - Eisai; Lilly; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Pierre Fabre; Roche/Genentech; Sotio
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)